A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

The primary objective of this study is: • To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

Inclusion Criteria

Subject must be willing and able to give written informed consent by signing an IRB approved Informed Consent Form prior to undergoing any study-specific procedures.
Subject must have completed all 24 weeks of participation in the study C-935788-057.

Exclusion Criteria

Any subject who discontinued participation in Study C-935788-057 prior to Week 24.

Additional locations may be listed on ClinicalTrials.gov for NCT04138927.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase III

Trial Typetreatment

Lead OrganizationRigel Pharmaceuticals

Primary IDC-935788-058
Secondary IDsNCI-2020-02017
ClinicalTrials.gov IDNCT04138927

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Inclusion Criteria

Exclusion Criteria

Have a question?
We're here to help

Which trials are right for you?

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help